Clozapine and Haloperidol Differently Suppress the MK-801-Increased Glutamatergic and Serotonergic Transmission in the Medial Prefrontal Cortex of the Rat
The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
The administration of noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine and ketamine has been shown to increase the extracellular concentration of glutamate and serotonin (5-HT) in the medial prefrontal cortex (mPFC). In the present work, we used in vivo microdialysis to examine the effects of the more potent noncompetitive NMDA receptor antagonist, MK-801, on the efflux of glutamate and 5-HT in the mPFC, and whether the MK-801-induced changes in the cortical efflux of both transmitters could be blocked by clozapine and haloperidol given systemically or intra-mPFC. The systemic, but not the local administration of MK-801, induced an increased efflux of 5-HT and glutamate, which suggests that the NMDA receptors responsible for these effects are located outside the mPFC, possibly in GABAergic neurons that tonically inhibit glutamatergic inputs to the mPFC. The MK-801-induced increases of extracellular glutamate and 5-HT were dependent on nerve impulse and the activation of mPFC AMPA/kainate receptors as they were blocked by tetrodotoxin and NBQX, respectively. Clozapine and haloperidol blocked the MK-801-induced increase in glutamate, whereas only clozapine was able to block the increased efflux of 5-HT. The local effects of clozapine and haloperidol paralleled those observed after systemic administration, which emphasizes the relevance of the mPFC as a site of action of these antipsychotic drugs in offsetting the neurochemical effects of MK-801. The ability of clozapine to block excessive cortical 5-HT efflux elicited by MK-801 might be related to the superior efficacy of this drug in treating negative/cognitive symptoms of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Paradoxically, MK-801 drives the increased release of glutamate in the mPFC, though the antipsychotic medications clozapine and haloperidol are both able to block MK-801-induced glutamate release in PFC of rats 169.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [169]
In the citing paper
“Paradoxically, MK-801 drives the increased release of glutamate in the mPFC, though the antipsychotic medications clozapine and haloperidol are both able to block MK-801-induced glutamate release in PFC of rats 169.”
From Mechanisms of synaptic transmission dysregulation in the prefrontal cortex: pathophysiological implications (2022) · cites this paper as [169]
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Cellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter
Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996) · Nature · doi:10.1038/379606a0 · Cited by 2,476
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 4×
“Thus, all these findings suggest that NMDA receptor antagonists would attenuate the tonic activation of inhibitory (GABA) neurons (possibly, though not exclusively, in the hippocampus and/or the thalamus), which would result in a disinhibition of glutamatergic input to the mPFC (Olney and Farber, 1995; Moghaddam et al…”
BackgroundInfluentialGeyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Prefrontal cortex in the rat: Projections to subcortical autonomic, motor, and limbic centers
Gabbott, P. L. A., Warner, T. A., Jays, P. R. L., Salway, P., & Busby, S. J. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20738 · Cited by 1,227 · cited 1×
“Furthermore, only around 5% of projection neurons in the V layer of the mPFC project to the dorsal raphe nucleus, according to Gabbott et al. (2005).”
Background
Cited by
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-053013-062946 · Cited by 422
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Bubeníková-Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 336
“MK-801 into rat prefrontal cortex lacked any effect on serotonin and glutamate levels (López-Gil et al., 2007).”
BackgroundYan, Z., & Rein, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01092-3 · Cited by 300
“Paradoxically, MK-801 drives the increased release of glutamate in the mPFC, though the antipsychotic medications clozapine and haloperidol are both able to block MK801-induced glutamate release in PFC of rats [169].”
BackgroundLinge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., Adell, A., & Díaz, Á. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.017 · Cited by 279
Self-citationGenetic variation in cortico-amygdala serotonin function and risk for stress-related disease
Holmes, A. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.006 · Cited by 264
Gillespie, A. L., Samanaite, R., Mill, J., Egerton, A., & MacCabe, J. H. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1177-y · Cited by 240
“One possible mechanism underlying the efficacy of clozapine in treatment-resistant illness may relate to its’ ability to attenuate glutamate release, as demonstrated in several rat studies [54, 55].”
BackgroundLieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X.-M., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 220
“Clozapine and haloperidol both blocked the MK-801-induced increase in glutamate in rat medial prefrontal cortex, whereas only clozapine was able to block the increased efflux of serotonin (López-Gil et al., 2007).”
BackgroundBrain NMDA Receptors in Schizophrenia and Depression
Adell, A. (2020) · Biomolecules · doi:10.3390/biom10060947 · Cited by 212
Self-citationMolecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 199
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
The acute effects of NMDA antagonism: From the rodent to the human brain
Gunduz-Bruce, H. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.006 · Cited by 182
Zhao, B.-W., Hu, L., You, Z.-H., Wang, L., & Su, X.-R. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab515 · Cited by 175
Fukumoto, K., Iijima, M., & Chaki, S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.233 · Cited by 174
Kargieman, L., Santana, N., Mengod, G., Celada, P., & Artigas, F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704848104 · Cited by 168
Self-citationPsychedelics and schizophrenia
González-Maeso, J., & Sealfon, S. C. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.005 · Cited by 166
Nakahara, T., Tsugawa, S., Noda, Y., Ueno, F., Honda, S., Kinjo, M., Segawa, H., Hondo, N., Mori, Y., Watanabe, H., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01297-6 · Cited by 179
Llado-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., & Celada, P. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr220 · Cited by 156
“Dialysate 5-HT concentration was determined by HPLC with amperometric detection (Hewlett-Packard 1049 detector, set at +0.7 V) as described previously (Amargo´s-Bosch et al. 2004; Lopez-Gil et al. 2007) with a detection limit of 4 fmol/sample.”
InfluentialSelf-citation1H-MRS at 4 Tesla in minimally treated early schizophrenia
Bustillo, J. R., Rowland, L. M., Mullins, P., Jung, R., Chen, H., Qualls, C., Hammond, R., Brooks, W. M., & Lauriello, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.121 · Cited by 153
Kim, E., Howes, O. D., Veronese, M., Beck, K., Seo, S., Park, J. W., Lee, J. S., Lee, Y., & Kwon, J. S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.258 · Cited by 146
“…patients (Demjaha et al, 2014; Mouchlianitis et al, 2016), suggests that glutamatergic differences could underlie the pathophysiology of treatment resistance, and is consistent with findings that clozapine acts on the glutamate system (Duncan et al, 1998; Javitt et al, 2005; Lopez-Gil et al, 2007).”
ResultIs the Acute NMDA Receptor Hypofunction a Valid Model of Schizophrenia?
Adell, A., Jiménez-Sánchez, L., López-Gil, X., & Romón, T. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr133 · Cited by 151
“In our lab, we have found that NMDA receptor antagonists–induced increase in 5-HT transmission in the prefrontal cortex is prevented by local or systemic administration of atypical, but not typical, antipsychotic drugs.(13,30) Based on this observation, we have hypothesized that an excessive prefrontal 5-HT transmissi…”
BackgroundSelf-citationPham, T. H., Mendez-David, I., Defaix, C., Guiard, B. P., Tritschler, L., David, D. J., & Gardier, A. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.010 · Cited by 136
“Although the functional relationship between the DRN and mPFCx is well documented (Lopez-Gil et al., 2007), further optogenetic experiments may help to confirm this hypothesis.”
40 Hz Auditory Steady-State Response Is a Pharmacodynamic Biomarker for Cortical NMDA Receptors
Sivarao, D. V., Chen, P., Senapati, A. K., Yang, Y., Fernandes, A., Benitex, Y., Whiterock, V. J., Li, Y.-W., & Ahlijanian, M. K. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.17 · Cited by 134
Egerton, A., Broberg, B. V., van Haren, N. E. M., Merritt, K., Barker, G. J., Lythgoe, D. J., Pérez‐Iglesias, R., Baandrup, L., Düring, S. W., Sendt, K.-V., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0082-9 · Cited by 146
Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development
Li, X., Frye, M. A., & Shelton, R. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.198 · Cited by 146
Höflich, A., Hahn, A., Küblböck, M., Kranz, G. S., Vanicek, T., Windischberger, C., Saria, A., Kasper, S., Winkler, D., & Lanzenberger, R. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv040 · Cited by 125
“…of the glutamatergic system propose that the blockage of NMDA receptors on GABAergic interneurons leads to a disinhibition of the activity of pyramidal cells, resulting in an increase of glutamate release within afferent and connected regions (Lorrain et al., 2003; Lopez-Gil et al., 2007).”
BackgroundGlutamate in schizophrenia: Neurodevelopmental perspectives and drug development
Egerton, A., Grace, A. A., Stone, J. M., Bossong, M. G., Sand, M. S., & McGuire, P. K. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.09.013 · Cited by 131
“chotic reserved for otherwise antipsychotic-resistant schizophrenia, may arise from its ability to reduce cortical glutamate levels or facilitate NMDAR activation (Abekawa et al., 2006; Amitai et al., 2012; Fukuyama et al., 2019; Javitt et al., 2005; López-Gil et al., 2007;Melone et al., 2001; Williams et al., 2004).”
Fukumoto, K., Iijima, M., & Chaki, S. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3378-0 · Cited by 107
Karlsson, R., Tanaka, K., Heilig, M. A., & Holmes, A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.001 · Cited by 107
Amitai, N., Kuczenski, R., Behrens, M. M., & Markou, A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.008 · Cited by 92
“…in our laboratory after systemic saline injections, and the existing literature reports no effects of such saline injections on extracellular glutamate levels in the PFC and other brain areas (e.g., Abekawa and Koyama, 2006; Abekawa et al., 2007; Adams and Moghaddam, 1998; Lopez-Gil et al., 2007).”
BackgroundResultDawson, N., Morris, B. J., & Pratt, J. A. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr144 · Cited by 90
de Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2921-8 · Cited by 89
“These behavioral effects due to NMDA receptor antagonists' administration have been partially related to increased glutamate levels in the mPFC (Moghaddam et al. 1997; Lorrain et al. 2003; Lopez-Gil et al. 2007).”
BackgroundEffect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia
Gururajan, A., TAYLOR, D. A. H. B., & Malone, D. T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.03.053 · Cited by 99
Neuroimaging findings in treatment-resistant schizophrenia: A systematic review
Nakajima, S., Takeuchi, H., Plitman, E., Fervaha, G., Gerretsen, P., Caravaggio, F., Chung, J. K., Iwata, Y., Remington, G. J., & Graff‐Guerrero, A. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.043 · Cited by 103
“…al. / Schizophrenia Research 164 (2015) 164–175 2012, 2007; Didriksen et al., 2007; Grayson et al., 2007;Hashimoto et al., 2005; Idris et al., 2005; Lopez-Gil et al., 2007), serotonin 5-HT2A receptors (Nordstrom et al., 1995), and dopamine D1 (Tauscher et al., 2004) or D4 receptors (Nord and…”
Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia
Kraguljac, N. V., Reid, M. A., White, D. M., den Hollander, J., & Lahti, A. C. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.126 · Cited by 84
Egerton, A., Bhachu, A., Merritt, K., McQueen, G., Szulc, A., & McGuire, P. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00066 · Cited by 84
Jiménez-Sánchez, L., Castañé, A., Pérez-Caballero, L., Grifoll, M., López-Gil, X., Campa, L., Galofré, M., Berrocoso, E., & Adell, A. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhv133 · Cited by 83
“…determined with HPLC coupled to electrochemical detection whereas glutamate and GABA were determined with HPLC coupled to fluorimetric detection (López-Gil et al. 2007; Masana et al. 2012). c-Fos Immunostaining c-Fos expression is considered to be a marker of neuronal activity (Dragunow and…”
Self-citationNeurobiological basis of motivational deficits in psychopathology
Salamone, J. D., Koychev, I. G., Correa, M., & McGuire, P. K. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.08.014 · Cited by 91
“However, clozapine may improve negative symptoms (Brar et al., 1997; Buchanan, 1995) and this has been attributed to its action on glutamate transmission (Lopez-Gil et al., 2007; Sumiyoshi et al., 2005; Tanahashi et al., 2012).”
BackgroundPratt, J. A., & Morris, B. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565805 · Cited by 81
“Acute administration of NMDA-R antagonists in rats also induces various effects on thalamocortical circuitry: (a) elevated glutamate release in the PFC, although the site of action of the NMDA-R antagonists appears to be outwith the PFC (Lopez-Gil et al., 2007; Lorrain et al., 2003); (b) c-fos induction in the PFC and…”
Fukuyama, K., Kato, R., Murata, M., Shiroyama, T., & Okada, M. (2019) · Biomolecules · doi:10.3390/biom9060234 · Cited by 83
“Several studies have demonstrated that the systemic administration of the non-competitive NMDA-R antagonists, phencyclidine [10], ketamine [11], and MK801 [12] increase glutamate release in the mPFC.”
BackgroundJiménez-Sánchez, L., Campa, L., Auberson, Y. P., & Adell, A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.123 · Cited by 85
“This and previous work from our lab demonstrated that the noncompetitive NMDA receptor antagonist, MK-801 induced stereotypies that were accompanied by an increased release of glutamate and 5-HT in the mPFC (López-Gil et al., 2007).”
InfluentialSelf-citationIn vivobrain microdialysis: advances in neuropsychopharmacology and drug discovery
Darvesh, A. S., Carroll, R. T., Geldenhuys, W. J., Gudelsky, G. A., Klein, J., Meshul, C. K., & der Schyf, C. J. V. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.547189 · Cited by 108
“Two recent studies from the Artigas laboratory have shown that the atypical APDs clozapine and olanzapine, but not haloperidol suppressed the NMDA antagonist-induced 5-HT and Glu efflux in the PFC [80,81].”
BackgroundLopez-Gil, X., Artigas, F., & Adell, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361416 · Cited by 77
“Acute NMDA receptor antagonism has also been reported to increase the release of glutamate [14-18], dopamine [19, 20], and serotonin (5-HT) [8, 16-18, 21, 22] in the medial prefrontal cortex (mPFC).”
BackgroundMethodInfluentialSelf-citationEffects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex
Yamamura, S., Ohoyama, K., Hamaguchi, T., Kashimoto, K., Nakagawa, M., Kanehara, S., Suzuki, D., Matsumoto, T., Motomura, E., Shiroyama, T., et al. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1601-9 · Cited by 78
Carli, M., & Invernizzi, R. W. (2014) · Frontiers in Neural Circuits · doi:10.3389/fncir.2014.00058 · Cited by 74
Yamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kakiuchi, T., Tsukada, H., & Domino, E. F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.176 · Cited by 76
“This result was consistent with previous microdialysis studies showing that a noncompetitive NMDA antagonist, dizocilpine (MK-801), in doses of 0.25–1 mg/kg, transiently increased serotonin levels about two times in the rat brain (López-Gil et al, 2007; Whitton et al, 1992; Yan et al, 1997).”
InfluentialHuang, M., Panos, J., Kwon, S., Oyamada, Y., Rajagopal, L., & Meltzer, H. Y. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12512 · Cited by 79
Santana, N., Troyano‐Rodriguez, E., Mengod, G., Celada, P., & Artigas, F. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.10.030 · Cited by 77
Self-citationBrandt, A. S., Unschuld, P. G., Pradhan, S., Lim, I. A. L., Churchill, G., Harris, A. D., Hua, J., Barker, P. B., Ross, C. A., van Zijl, P. C. M., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.017 · Cited by 77
Salavati, B., Rajji, T. K., Price, R., Sun, Y., Graff‐Guerrero, A., & Daskalakis, Z. J. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu132 · Cited by 77
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
McQueen, G., Sendt, K.-V., Gillespie, A. L., Avila, A., Lally, J., Vallianatou, K., Chang, N., Ferreira, D., Borgan, F., Howes, O. D., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa156 · Cited by 78
A unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 78
“This view is based on the initial findings that the administration of ketamine in rats increases glutamate release in the medial prefrontal cortex (PFC) concomitant with an increase in the firing rate of pyramidal neurons in this brain area (López-Gil et al., 2007; Moghaddam et al., 1997).”
BackgroundHiyoshi, T., Kambe, D., Karasawa, J.-I., & Chaki, S. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.037 · Cited by 72
Gasull-Camós, J., Tarrés-Gatius, M., Artigas, F., & Castañé, A. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.7 · Cited by 62
Self-citationMocci, G., Jiménez-Sánchez, L., Adell, A., Cortés, R., & Artigas, F. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.10.021 · Cited by 70
“Glutamate concentration was determined using a HPLC system which consisted of a Waters 717plus autosampler, a Waters 600 quaternary gradient pump, and a Nucleosil 5-mM ODS column (10 cm x 0.4 cm; Teknokroma, Spain), as previously described (López-Gil et al., 2007)”
InfluentialSelf-citationLópez-Gil, X., Artigas, F., & Adell, A. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009267 · Cited by 70
Self-citationBlot, K., Kimura, S.-I., Bai, J., Kemp, A., Manahan-Vaughan, D., Giros, B., Tzavara, E., & Otani, S. (2015) · Cerebral Cortex · doi:10.1093/cercor/bht329 · Cited by 58
“Studies demonstrated that systemic injection of MK-801 increases dopamine and glutamate effluxes in the mPFC (Wedzony et al. 1993; Lopez-Gil et al. 2007; Roenker et al. 2012), as in the case for tetanus-induced LTP in HPC– mPFC pathway (Gurden et al. 2000).”
BackgroundRoenker, N. L., Gudelsky, G. A., Ahlbrand, R., Bronson, S. L., Kern, J. R., Waterman, H., & Richtand, N. M. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.06.011 · Cited by 73
“Additionally, because antipsychotic medications with prominent D2 receptor binding and more limited 5HT2A receptor affinity such as haloperidol also protect against MK-801-mediated glutamate elevation [21], an independent mechanism mediating this effect through dopamine D2 receptor blockade has also been suggested.”
BackgroundResultJiménez-Sánchez, L., Linge, R., Campa, L., Valdizán, E. M., Pazos, Á., Díaz, Á., & Adell, A. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.020 · Cited by 66
Self-citationThe prefrontal cortex: a target for antipsychotic drugs
Artigas, F. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01455.x · Cited by 61
“Moreover, MK-801 reduces the activity of fast-spiking interneurons in PFC, which suggests that, in addition to network-based effects, NMDA receptor blockade in certain PFC interneurons may contribute to the enhancement of the activity of pyramidal neurons (89).”
BackgroundInfluentialSelf-citationLeading compounds for the validation of animal models of psychopathology
Micale, V., Kučerová, J., & Šulcová, A. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1692-9 · Cited by 61
Ma, D., Chan, M. K., Lockstone, H. E., Pietsch, S. R., Jones, D. N. C., Cilia, J., Hill, M. D., Robbins, M. J., Benzel, I. M., Umrania, Y., et al. (2009) · Journal of Proteome Research · doi:10.1021/pr800983p · Cited by 56
Zhang, C., & Marek, G. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.009 · Cited by 65
Yamamura, S., Ohoyama, K., Hamaguchi, T., Nakagawa, M., Suzuki, D., Matsumoto, T., Motomura, E., Tanii, H., Shiroyama, T., & Okada, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00175.x · Cited by 55
“…which is mainly and antagonist at dopamine D2 receptors (Bymaster et al., 1997), are in agreement in general with those reported by previous British Journal of Pharmacology (2009) 157 656–665 investigators (Rowley et al., 2000; Zhang et al., 2000; Adams and Moghaddam, 2001; Lopez-Gil et al., 2007).”
BackgroundResultClozapine and GABA transmission in schizophrenia disease models
O'Connor, W. T., & O’Shea, S. D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.005 · Cited by 62
Serotonin in antipsychotic drugs action
Amato, D. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.025 · Cited by 58
Okada, M., Fukuyama, K., Kawano, Y., Shiroyama, T., & Ueda, Y. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.457 · Cited by 52
Bonaventure, P., Aluisio, L., Shoblock, J., Boggs, J. D., Fraser, I. C., Lord, B., Lovenberg, T. W., & Galici, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020210 · Cited by 51
“Antipsychotics attenuate MK-801-induced glutamate release in the cortex [28], which may mediate some aspects of their clinical efficacy.”
BackgroundOhoyama, K., Yamamura, S., Hamaguchi, T., Nakagawa, M., Motomura, E., Shiroyama, T., Tanii, H., & Okada, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.11.023 · Cited by 53
Pozzi, L., Baviera, M., Sacchetti, G., Calcagno, E., Balducci, C., Invernizzi, R. W., & Carli, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2010.11.060 · Cited by 49
The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
Egerton, A., & M. Stone, J. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784961 · Cited by 49
“Disinhibition of pyramidal neuron activity would be expected to result in increased glutamate release - and microdialysis studies consistently show that systemic administration of NMDAR antagonists increases glutamate release in frontal cortical regions [101-104].”
BackgroundFernández‐García, S., Conde-Berriozabal, S., García-García, E., Gort‐Paniello, C., Bernal‐Casas, D., Barriga, G. G.-D., López-Gil, X., Muñoz‐Moreno, E., Sòria, G., Campa, L., et al. (2020) · eLife · doi:10.7554/elife.57017 · Cited by 50
Self-citationSumiyoshi, T., Bubeníková‐Valešová, V., Horáček, J., & Bert, B. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0102-2 · Cited by 50
Roenker, N. L., Gudelsky, G. A., Ahlbrand, R., Horn, P. S., & Richtand, N. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.032 · Cited by 47
“Although basal extracellular glutamate has been shown to be unaltered by tetrodotoxin (TTX), the MK-801-induced increase in glutamate was shown to be markedly attenuated by TTX (Lopez-Gil et al., 2007).”
BackgroundInfluentialKetamine-dependent neuronal activation in healthy volunteers
Höflich, A. S., Hahn, A., Küblböck, M., Kranz, G. S., Vanicek, T., Ganger, S., Spies, M., Windischberger, C., Kasper, S. F., Winkler, D., et al. (2016) · Brain Structure and Function · doi:10.1007/s00429-016-1291-0 · Cited by 50
Decreased Brain pH and Pathophysiology in Schizophrenia
Park, H. J., Choi, I., & Leem, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168358 · Cited by 54
“The decreased brain pH is also expected to induce hypofunction of NMDA receptors, which decreases GABAergic inhibition of glutamatergic inputs to the PFC and results in increased glutamate release.”
BackgroundInfluentialHarms, L., Parras, G. G., Michie, P. T., & Malmierca, M. S. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2020.01.046 · Cited by 43
Blot, K., Bai, J., & Otani, S. (2013) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2013.04.003 · Cited by 46
“This would explain why local infusion of MK-801 does not increase the efflux of glutamate in the mPFC (Lopez-Gil et al., 2007).”
BackgroundPratt, J. A., Dawson, N., Morris, B. J., Grent-‘t-Jong, T., Roux, F., & Uhlhaas, P. J. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.05.013 · Cited by 48
“However, various lines of evidence suggest a primary site of action for NMDA-R antagonists that is outwith the PFC (Lopez-Gil et al., 2007; Lorrain et al., 2003; Rotaru et al., 2011).”
Ćurĉić‐Blake, B., Bais, L., Sibeijn‐Kuiper, A., Pijnenborg, H. M., Knegtering, H., Liemburg, E. J., & Aleman, A. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.05.020 · Cited by 44
“cortex (Lopez-Gil et al., 2007) and that antipsychotic medication downregulates the Glx levels in medial prefrontal cortex (Kegeles et al.”
Mørk, A., Witten, L. M., & Arnt, J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1578-4 · Cited by 40
“Accordingly, acute administration of the NMDA antagonist, MK-801, increased the extracellular levels of Glu in the mPFC (Lopez-Gil et al. 2007; Zuo et al. 2006), while repeated administration of MK-801 decreased Glu levels in the mPFC (Zuo et al. 2006).”
BackgroundFrancesconi, L. P., Ceresér, K. M., Mascarenhas, R., Stertz, L., Gama, C. S., & Belmonte-de-Abreu, P. S. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.06.042 · Cited by 40
Kubota, M., Moriguchi, S., Takahata, K., Nakajima, S., & Horita, N. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.03.069 · Cited by 41
Romón, T., Mengod, G., & Adell, A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2268-6 · Cited by 40
“Acute administration of NMDA receptor antagonists including PCP, ketamine and MK-801 is also used to recapitulate the symptoms of schizophrenia in behavioral assays (Swerdlow et al. 1994; Corbett et al. 1995; Abekawa et al. 2003; Jackson et al. 2004; López-Gil et al. 2007).”
BackgroundMethodSelf-citationFukuyama, K., Hasegawa, T., & Okada, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113645 · Cited by 37
“Systemic administration of non-competitive NMDAR antagonists phencyclidine [19], ketamine [21], and MK801 [22] increases L-glutamate release in the mPFC.”
BackgroundCalcagno, E., Carli, M., Baviera, M., & Invernizzi, R. W. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05789.x · Cited by 35
“3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid raised extracellular 5-HT in the mPFC, an effect shared by other NMDA receptor antagonists, such as phencyclidine, ketamine, and MK-801 (Martin et al. 1998b; Adams and Moghaddam 2001; Lopez-Gil et al. 2007).”
BackgroundInfluentialLópez-Gil, X., Jiménez-Sánchez, L., Romón, T., Campa, L., Artigas, F., & Adell, A. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001064 · Cited by 33
“…NMDA antagonists also induced behavioural activation and enhanced the efflux of glutamate and 5-HT in the mPFC (Adams & Moghaddam, 2001; López-Gil et al. 2007; Lorrain et al. 2003; Moghaddam et al. 1997), effects that were not observed following the unilateral intra-mPFC perfusion of…”
InfluentialSelf-citationEngel, M., Snikeris, P., Jenner, A. M., Karl, T., Huang, X., & Frank, E. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu114 · Cited by 34
“However, local clozapine and haloperidol administration have been reported to reduce GABA levels, with clozapine, but not haloperidol, also increasing glutamate levels in the PFCs of rats (Bourdelais and Deutch, 1994; López-Gil et al., 2007).”
BackgroundHuang, M., He, W., Kiss, B., Farkas, B., Adham, N., & Meltzer, H. Y. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.259879 · Cited by 37
Hiyoshi, T., Kambe, D., Karasawa, J., & Chaki, S. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.08.047 · Cited by 33
“In addition, the inhibitory effects of haloperidol and clozapine on MK-801-increased glutamate release occurred even during the intra-PFC perfusion of these drugs (López-Gil et al., 2007).”
InfluentialCelada, P., Lladó-Pelfort, L., Santana, N., Kargieman, L., Troyano‐Rodriguez, E., Riga, M. S., & Artigas, F. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000643 · Cited by 36
“Moreover, the systemic, but not local, administration of non-competitive NMDA receptor antagonists increased neurotransmitter release in PFC (AmargosBosch et al., 2006; Lopez-Gil et al., 2007) suggesting that NMDA receptor blockade in other brain areas may also contribute to increased PFC activity.”
BackgroundSelf-citationmTOR Knockdown in the Infralimbic Cortex Evokes A Depressive-like State in Mouse
Garro-Martínez, E., Fullana, M. N., Florensa-Zanuy, E., Senserrich, J., Paz, V., Ruiz‐Bronchal, E., Adell, A., Castro, E., Díaz, Á., Pazos, Á., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168671 · Cited by 32
“5-HT and Glu were determined by HPLC, as previously described [91].”
MethodSelf-citationPen, G. L., Jay, T. M., & Krebs, M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110387839 · Cited by 39
“The increase in glutamate outflow in the mPFC induced by systemic MK-801 administration has been shown to be prevented by local administration of clozapine and haloperidol (Lopez-Gil et al., 2007; Scorza et al., 2008).”
BackgroundAmargós‐Bosch, M., Adell, A., & Artigas, F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04532.x · Cited by 31
“…glutamate release in mPFC, also increase 5-HT neuron activity (Lejeune et al. 1994) and 5-HT release in mPFC (Martin et al. 1998; Ceglia et al. 2004; AmargósBosch et al. 2006; Lópz-Gil et al. 2007) an effect blocked by the application of the AMPA antagonist NBQX in mPFC (Lópz-Gil et al. 2007).”
BackgroundSelf-citationLiu, X., Li, J., Guo, C., Wang, H., Sun, Y., Wang, H., Su, Y., Li, K., & Si, T. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00260 · Cited by 34
Antipsychotic treatment modulates glutamate transport and NMDA receptor expression
Zink, M., Englisch, S., & Schmitt, A. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-014-0534-4 · Cited by 30
Hornig, T., Grüning, B. A., Kundu, K., Houwaart, T., Backofen, R., Biber, K. P. H., & Normann, C. (2017) · Genetics Research · doi:10.1017/s0016672316000148 · Cited by 28
“In experimental animals, acute blockade of glutamatergic transmission affects the dopaminergic system and induces hyper-dopaminergic conditions in distinct regions of the cerebral cortex (Moghaddam & Adams, 1998; López-Gil et al., 2007).”
BackgroundPham, T. H., Defaix, C., Nguyen, T. M. L., Mendez‐David, I., Tritschler, L., David, D. J. P., & Gardier, A. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172913 · Cited by 30
Rivera-García, M. T., López‐Rubalcava, C., & Cruz, S. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4041-8 · Cited by 28
“MK-801 also increases 5-HT and DA release in nucleus accumbens and mPFC (López-Gil et al. 2007; Mathé et al. 1996; Schmidt and Fadayel 1996; Yan et al. 1997), which suggests that a similar effect could have been produced by toluene in the present study.”
BackgroundExamination of ketamine-induced deficits in sensorimotor gating and spatial learning
Sabbagh, J. J., Heaney, C. F., Bolton, M. M., Murtishaw, A. S., & Kinney, J. W. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.08.007 · Cited by 30
“However, there is considerable variability in the ability to effectively model the disruptions in schizophrenia depending on the specific NMDA receptor antagonist selected [18,59,71,72].”
Background
Metadata
- Authors
- López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Corresponding author
- Adell, Albert
- Venue
- Neuropsychopharmacology
- Published
- 2007-03-14
- Volume
- 32
- Issue
- 10
- Pages
- 2087-2097
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2084299214
- Cited by
- 183
- References
- 89
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 10 · 2017: 7 · 2016: 13 · 2015: 10 · 2014: 16 · 2013: 13 · 2012: 7
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Funders
- Generalitat de Catalunya (SGR-2005)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- clozapine, haloperidol, MK-801, NMDA receptor antagonists, medial prefrontal cortex, glutamate efflux, serotonin efflux, non-NMDA receptors, antipsychotic drugs, negative symptoms of schizophrenia, cognitive symptoms, tetrodotoxin, NBQX, local drug administration
- MeSH terms
- Animals, Clozapine, gamma-Aminobutyric Acid, Haloperidol, Male, Synaptic Transmission, Schizophrenia, Serotonin, Antipsychotic Agents, Dizocilpine Maleate, Rats, Wistar, Prefrontal Cortex, Microdialysis, Receptors, AMPA, Excitatory Amino Acid Antagonists, Glutamic Acid, Extracellular Fluid, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.